Several biomarkers, such as tumor mutation burden (TMB), PD‐L1 expression, microsatellite instability and tumor neoantigen‐related mutation burden (TNB), can be used to screen for patients who can benefit the most from immunotherapy. This evidence concerns the gene CD274 and neoplasm.